Smart Screening in Prostate Cancer: What We Have Learned So Far from PROBASE
European Urology Focus · 2026-04
DOI: 10.1016/j.euf.2026.04.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Urology Focus, 2026-04. Verfasst von Rouvier Al-Monajjed und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany; Division of Personalized Early Dete…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Abstract (Originalsprache)
Smart prostate cancer screening means screening better: risk stratification, prostate-specific antigen confirmation, expert magnetic resonance imaging, and prostate-specific antigen density-guided biopsy reduce harm without compromising detection of significant disease.
Autor:innen und Institutionen
- Department of Urology, University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany; Division of Personalized Early Detection of Prostate Cancer, German Cancer Research Center (DKFZ), Heidel…
- Division of Personalized Early Detection of Prostate Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Zitieren
APA
Al-Monajjed, R., Krilaviciute, A., Albers, P., & PROBASE study group (2026). Smart Screening in Prostate Cancer: What We Have Learned So Far from PROBASE. European Urology Focus. https://doi.org/10.1016/j.euf.2026.04.008
Vancouver
Al-Monajjed R, Krilaviciute A, Albers P, PROBASE study group. Smart Screening in Prostate Cancer: What We Have Learned So Far from PROBASE. European Urology Focus. 2026. doi:10.1016/j.euf.2026.04.008
BibTeX
@article{AlMonajjed2026,
author = {Al-Monajjed, Rouvier and Krilaviciute, Agne and Albers, Peter and PROBASE study group, PROBASE study group},
title = {Smart Screening in Prostate Cancer: What We Have Learned So Far from PROBASE},
journal = {European Urology Focus},
year = {2026},
doi = {10.1016/j.euf.2026.04.008}
}
EUVIMED